The global mucormycosis treatment market is growing at a CAGR of 6.5% during the forecast period. One of the major factors that are augmenting the growth of the mucormycosis treatment market is the increasing rising incidence of immunological diseases. Moreover, the growing preference due to the availability of a wide range of products along with the growing awareness associated with fungal infection is also estimated to be the other important factor that is contributing significantly towards the growth of the market. However, high-cost involvement of treatment and side effects of the drugs are some factors constraints that are hindering the growth of the global mucormycosis treatment market across the globe. 

Moreover, modernization in the healthcare sector in emerging regions are some of the key factors that are creating opportunities for the market. A new offering in the market is likely to drive the growth of the global mucormycosis treatment market. For instance, in December 2021, Sun Pharmaceutical Industries Ltd., had received approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for generic Amphotericin B Liposome as injection with 50 mg/vial single-dose vial. Amphotericin B is regarded as an antifungal medication used for serious fungal infections and leishmaniasis. The fungal infections it is used to treat include mucormycosis, candidiasis, coccidioidomycosis, and cryptococcosis among others.

Impact of COVID-19 Pandemic on Global Mucormycosis Treatment Market  

The COVID-19 pandemic had impacted various industries in an adverse manner. The COVID-19 pandemic in these major economies has disrupted manufacturing and transportation across the globe. However, the risk of infection related to mucormycosis is impacting more to the recovered patients from COVID-19 owing to steroid medications. Additionally, COVID-19 patients suffering from diabetes and pre-existing more than one disease are revealed to steroid and humidified oxygen for an expanded period are at a high risk of mucormycosis which in turn is supporting in the favor of the market.

Segmental Outlook 

The market is segmented based on diagnosis, treatment, and end-user. By diagnosis, the market is segmented into computed tomography (CT), magnetic resonance imaging (MRI), and tissue biopsy. Further, based on the treatment segment, the market is segmented into surgery and antifungal drugs. Based on the end-user segment, the market is divided into hospitals & clinics, and research institutes.

Global Mucormycosis Treatment Market Share Treatment, 2021 (%)

Antifungal Drugs Expected to Hold Prominent Market Share in the Global Mucormycosis Treatment Market  

Based on the treatment, the antifungal drugs segment holds a significant share in the mucormycosis treatment market. Generally, 2 main classes of antifungal drugs are regarded for the purpose of providing treatment of mucormycosis which include polyenes (amphotericin formulations) and triazoles (isavuconazole and posaconazole). Generally, these medicines are given through a vein or by mouth. Additionally, FDA had also approved the primary therapy of mucormycosis for Amphotericin B and isavuconazole.

Regional Outlooks

The global mucormycosis treatment market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in the global Mucormycosis Treatment Market. Some factors that are boosting the market growth in North America are technologically advanced products and the present increasing cases related to mucormycosis. For instance, as per the information provided by medical literature, the incidence of mucormycosis is increasing and one of the estimates that were based on a study in the San Francisco area had highlighted the incidence that 1.7 people per every 1,000,000 in the general population are suffering. This incidence refers to the number of new diagnoses of a disorder in one year. Additionally, the existence of a large number of players providing effective offerings is some other main factor that is providing support to the growth of the market in the region.

Global Mucormycosis Treatment Market Growth, by Region 2022-2028 

Asia-Pacific will have considerable growth in the Global Mucormycosis Treatment Market   

The Asia-Pacific region is expected to witness significant growth opportunities for the market. Improving health care infrastructure along with increasing cases associated with mucormycosis among people is acting as the prime factor impacting the market in the region. Additionally, technology advancement and industry players are having large scope in this region especially in South Korea, China, and India for increasing their activity in the market.

Market Players Outlook

The prominent players functioning in the global mucormycosis treatment market include Cadila Pharmaceuticals, CELON LABS, Lifecare Innovations Pvt. Ltd., Merck Sharp & Dohme Corp., and Sun Pharmaceutical Industries Ltd. among others. These key manufacturers are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships, and collaborations, and many others to thrive in a competitive environment. For instance, in December 2021, Pfizer Inc., had received the drug approval license for its oral formulation of its antifungal Cresemba (isavuconazole) from the National Medical Products Administration (NMPA) in China. With the approval in China for Cresemba in order to provide effective treatment to adult patients with invasive mucormycosis.

In March 2021, Bharat Serums & Vaccines (BSV) had received authorization from the Drugs Controller General of India (DCGI) for Liposomal Amphotericin B which is regarded as an antifungal medicine used for the treatment of mucormycosis. 

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global mucormycosis treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.